Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Phase4 Spins Out Of Nomura To Focus On Europe

This article was originally published in Start Up

Executive Summary

When the management team at Phase4 Ventures in February 2011 spun the venture capital business out of parent Nomura, the move highlighted two important features of the VC landscape. The first is continued investor interest in Europe, which will replace the US as Phase4's primary geographic focus, and the second is the growing, and increasingly creative, role for large secondary players in the still-vulnerable VC sector.
Advertisement

Related Content

Euro Crisis Hits Investor Risk Appetite, But Opportunities Remain
Amgen Takes Out Cancer Vaccine Developer BioVex In Potential $1B Deal
Amgen Takes Out Cancer Vaccine Developer BioVex In Potential $1B Deal
Phenomix Folds After Diabetes Drug Fails To Attract Partner To Fill Forest's Shoes
Phenomix Folds After Diabetes Drug Fails To Attract Partner To Fill Forest's Shoes

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC092094

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel